Section Menu  
Doctors Corner
Mission
Advisory Board
Journal Room
Guidelines
Sites of Interest
Register
Dermatologist?
CPD Guidelines
Melanoma Fact Sheet
Events
Gallery
 Vichy Health

Protection from UV Damage Pamphlet
 Powered by
 
Related SA Websites 
 Guidelines
  1. INTRODUCTION
  2. PREVENTION
  3. CLINICAL DIAGNOSIS OF MELANOMA
  4. SURFACE MICROSCOPY
  5. SCREENING AND SURVEILLANCE
  6. FAMILIAL RISK AND FAMILY SURVEILLANCE
  7. BIOPSY OF PIGMENTED LESIONS
  8. CONGENITAL MELANOCYTIC NAEVI
  9. LENTIGO MALlGNA
  10. HISTOPATHOLOGICAL REPORT
  11. CLASSIFICATION OF MELANOMA
  12. TREATMENT OF PRIMARY MELANOMA
  13. SURVIVAL OUTCOMES OF PRIMARY MELANOMA MANAGEMENT
  14. TREATMENT OF LYMPH NODES
  15. OCCULT PRIMARY MELANOMA
  16. LOCOREGIONAL RECURRENT MELANOMA
  17. ADJUVANT THERAPY
  18. DISSEMINATED MELANOMA
  19. RADIOTHERAPY FOR MELANOMA
  20. PALLIATIVE CARE
  21. FOLLOW UP
  22. APPROPRIATE INVESTIGATIONS
  23. SPECIFIC SITES AND TYPES OF MELANOMA







Dagmar K. Whitaker M.D. Dermatologist; Werner Sinclair M.Med Dermatologist; Daniel Vorobiof M.D. Oncologist; Graham Cohen FCP(SA) Medical Oncologist; David Presbury FRCP Dermatologist; Peter Scott FRCS Plastic Surgeon; Helen Stubbings Oncologist; Charles Thatcher FFPath Pathologist; Prof A. Giraud FRCS General Surgeon; Brian Ritchie FRCS Plastic Surgeon; Constant Nel Oncologist; Gary Levy FFDerm Dermatologist

  1. INTRODUCTION

Invasive primary malignant melanoma in whites shows the greatest and most rapid increase of all cancer worldwide. The incidence in South Africa is unknown but what is known is that the incidence in the Cape Town area is similar to that of Australia (24.4 per 100,000) and epidemiological studies, to determine the exact incidence are in progress. In Australia it is one fo the most common cancers 1-3 with the estimated risk of developing a melanoma before the age of 75 (in 1993) being 1 in 27 for males and 1 in 36 for females.3

Melanoma is therefore an important clinical and health problem and it is essential that the management of the disease is as effective as possible. These clinical practice guidelines are designed to assist those involved in the management of this common cancer to provide optimum management for their patients. They are based on the guidelines developed and published by the Australian Cancer Network 4 and have been summarised and adapted as follows.
 

Back to contents>>

  1. PREVENTION

Exposure to sunlight is strongly associated with the development of melanoma.5 The pattern of exposure is important, with intermittent exposure being more closely linked to the development of melanoma than the regular patterns of exposure of the outdoor worker.5 The action spectrum, which is causative for melanoma, in particular the relative roles of UVB and UVA, is as yet unknown. However in animal models, UVA has been found to be a highly significant component in melanoma induction.6,7 In addition the use of sunbeds which deliver mainly UVA radiation may be arisk factor for melanoma.8

The following protection measures are recommended:

  • Physical protection should be the primary preventative measure. Avoid direct exposure to sunlight during the two hours either side of solar noon.
  • Use sun protective clothing when exposed to direct sunlight for periods greater than 15 minutes.
  • People should be advised to choose dark clothing of closely woven fabrics which is more protective than light loosely woven garments. Fabrics with an inbuilt protection factor are available in i.e. sports/diving/climbing shops.
  • Use broad spectrum sunscreens as an adjunct to sun avoidance and other sun protective measures. New sunscreens should contain a UVA as well as UVB screen and in contrast to previous recommendations that a factor 15 is adequate the advise is : The higher the factor the better (> SP30).
  • Provide and use sun protective structures (eg. shade structures) whenever possible.
  • Provide children with appropriate sun protection for outdoor activities. Emphasis should be placed on the protection of children and adolescence from excessive sunlight exposure.9 Sunlight exposure at this age is closely related to the development of naevi. The presence of multiple naevi is a strong risk factor for melanoma.10-14
  • Advise against the use of sunbeds, tanning booths and tanning lamps. These deliver mainly UVA radiation and UVA radiation causes DNA mutation which is a predisposing factor for subsequent carcinogenic UVB damage.
 

Back to contents>>

  1. CLINICAL DIAGNOSIS OF MELANOMA
The dignosis of melanoma should be considered in all cases of pigmented or chainging lesions on the skin. The key to the clinical diagnosis of a pigmented melanoma is irregularity of the lesion. Irregularity of colour is most important and the presence of a variet of colours in any one lesion is a key feature. While a black or blue/black colour is the most common, many other shades of brown, blue, red, grey or white are often seen. Irregularity of outline is the second most common feature with indentations and outgrowths around the lesion often apparent. Irregularity of the surface is another important sign. Amelanotic melanoma is clinically difficult to diagnose, usually appearing as an enlarging smooth reddish nodule or patch. Sometimes an area of brown pigment can be discerned in these lesions. Surface microscopy may be helpful.

The ABCDE system of diagnosis of melanoma has gained general support.17,18
A = ASYMMETRY
A lesion is asymmetric if opposite segments of the lesion are appreciably different.
B = BORDER
The border of a melanoma is usually irregular, resembling a coastline with bays and promontories around the edge. All or part of the border is often well defined, in contrast with the dysplastic naevus, whose border is often ill–defined and fades into the background of the surrounding tissues.
C = COLOUR
Variation in colour is an important feature. A narrow red halo is sometimes seen around the edge of a melanoma. It is important to remember that amelanotic melanoma will have little or no distinguishing colour.
D = DIAMETER
Superficial spreading melanomas are often greater than 6mm in diameter when first diagnosed, but it is possible to diagnose smaller melanomas, particularly nodular lesions, which appear not only as small shiny dark nodules but can also be reddish in amelanotic forms.


E = ELEVATION
While E designates elevation, it is important to diagnose melanoma while it is flat or with marginal elevation. At that stage the lesion is more likely to be curable. Thus E should remind the clinician to ‘Examine’ the patient’s other pigmented lesions.
A feature which may be helpful in diagnosing melanomas is a ‘ground glass’ amorphous appearance to part of the lesion. Where the skin lines have been destroyed by the tumours, a shiny, glassy appearance is noted. Many melanomas will also have small flakes of keratin on the surface but it is extremely rare for the lesion to be extensively keratinised. The presence of hairs does not exclude a diagnosis of melanoma, but most pigmented lesions with hairs are benign. However, more advanced melanomas will not have hair in the deeply invasive parts of the tumour because the melanoma will destroy the hair follicles as it invades. Thick melanomas are firm to touch and not compressible, unlike haemangiomas, and are rarely waxy to feel, unlike a seborrhoeic keratosis.

The differential diagnosis of pigmented melanoma includes dysplastic naevus, Spitz naevus, pigmented basal cell carcinoma, blue naevus, haemangioma, pigmented seborrhoeic keratosis and some rare adnexal tumours. In children, pigmented Spitz naevus is a likely diagnosis.

The amelanotic or hypomelanotic tumour differential diagnosis includes dermatofibroma, desmoplastic melanoma, basal cell carcinoma and other spindle cell tumours.
  • Good lighting and magnification is recommended when lesions are being examined.
  • All clinicians should become trained in the recognition of early melanoma.
  • A good clinical history of change in the lesion, if any, a past history of skin lesions, and a family history of melanoma should be obtained. A family history is defined as melanoma in a direct line family member -grandparent, parent, sibling or child of the patient.
  • Refer for a specialist opinion or biopsy lesions which are suspicious. High risk individuals should be advised on the specific changes which suggest melanoma and encouraged to undertake self examination.
  • Take note of any recent change or sensation reported by the patient.

 

Back to contents>>

  1. SURFACE MICROSCOPY
  • Skin surface microscopy should be carried out by Specialists who have had specific training and are experienced due to the highly specialised nature of this examination. (Dermatoscope) 19-23
  • Digital Epiluminescence Microscopy (Molemax) can be used to monitor high risk patients because it allows to view morphological features (colours, pigmentation pattern) not seen with traditional surface microscopy and it is an effective documentation system.

 

Back to contents>>

  1. SCREENING AND SURVEILLANCE
Risk factors for development of melanoma include a family history of melanoma, fair complexion, a tendency to burn rather than tan, the presence of freckles, the presence of solar lentigines, light eye colour, light or red hair colour and a past history of non-melanoma skin cancer. 24-26

All individuals who are at high risk for the development of melanoma should be advised about the changes that might suggest the development of an early melanoma, encouraged to undertake regular self examination and advised regarding appropriate methods of sun protection.

The presence of large numbers of melanocytic naevi and the presence of clinically determined atypical or dysplastic naevi are very strong risk factors for melanoma.13, 24-27 Dysplastic naevi are generally larger than normal moles with ill-defined edges and irregular pigmentation, which is mostly shades of brown.28 They tend to have a poorly defined edge.28 Melanoma risk increases with increasing numbers of total naevi and dysplastic naevi.13,24-27 The risk associated with clinical dysplastic naevi has been shown to be independent of that associated with the total numbers of naevi.27 Clinically dysplastic naevi are not always dysplastic on histopathological examination.

Prophylactic excision of dysplastic naevi and other benign naevi is not useful in minimizing melanoma risk. A significant proportion of melanomas begin as new lesions rather than developing from pre-exsiting naevi.29-31

  • Consider referral of these high risk individuals a specialist with an interest in melanoma management

 

Back to contents>>

  1. FAMILIAL RISK AND FAMILY SURVEILLANCE

Recent Australian data indicate that 10% of melanoma cases will have at least one (and most only one) confirmed melanoma-affected first degree relative 32, potentially resulting from inheritance of uncommon, major melanoma susceptibility gene(s). 33 Consider referral of family members with a strong history of melanoma among close relatives, particularly with large numbers of naevi, to a specialist with interest in melanoma management and refer for genetic studies if available.

 

Back to contents>>

  1. BIOPSY OF PIGMENTED LESIONS
  • Biopsy of pigmented lesions should be done only on the basis of suspicious clinical features. Prophylactic excision of clinically benign lesion is not recommended. Primary biopsy should always be performed by complete excision.
  • Shave and punch biopsies of pigmented lesions should be avoided
  • Lesions suspected to be melanoma should be excised with a 2 mm lateral margin and to the depth of the upper layer of the fat.
  • Where doubt exists, a period of observation based on the history and clinical features of the lesion is acceptable. The period of observation will be short if a high level of suspicion of melanoma is present. However, if the clinician feels the lesion is unlikely to be melanoma and it does not change, it is appropriate to continue observation until the evidence of change appears.
  • If melanoma is suspected, referral for a specialist opinion, where available should be considered before biopsy is undertaken.

 

Back to contents>>

  1. CONGENITAL MELANOCYTIC NAEVI

Congenital naevi are present at birth and are diagnosed with specific histological features.34-36 The lesions are arbitrarily divided into three groups based on diameter: <1.5 cm, 1.5–20 cm and 20+ cm.

SMALL(<1.5 cm) lesions occur in 1% of births. They are not thought to have an increased malignant potential. 31-36

MEDIUM (1.5 – 20 cm) lesions have not been subject to adequate research so the malignant potential of this group is unclear. 37-38 If excision is undertaken, it should be during the teenage years, since a study of 31 patients with melanomas arising from small congenital naevi (1.5–10cm) found none of these melanomas presenting before puberty. However, at this stage, the body of evidence suggests that observation only is required.

LARGE(>20 cm) lesions. There are only two prospective studies addressing these lesions. These show a crude risk of 3%. 39-41 A literature review 8 has shown that 70% of melanomas in this group develop before puberty.

Superficial removal of the naevus by dermabrasion or tangential excision is not recommended as two-thirds of melanoma develop in non-epidermal sites. 42,43

Patients with large congenital naevi of the head and neck are also at risk from neurocutaneous melanosis. 44

An MRI scan should be considered for screening these patients. 45 Lifelong surveillance for large and possibly for medium congenital naevi is recommended.
  • Excisional biopsy of suspicious areas in large congenital naevi is recommended but should be carried out at a specialist centre.
  • Surgical excision of congenital naevi is appropriate where patient concern is high and where an acceptable cosmetic outcome can be achieved.
The removal of large naevi for cosmetic reasons only has no contra-indications provided the patient is made fully aware of the likely appearance of the end result

 

Back to contents>>

  1. LENTIGO MALlGNA

Lentigo maligna (Hutchinson’s melanotic freckle) is a common pigmented lesion on the exposed skin of the older patient. These lesions are regarded as in-situ melanoma and may progress to invasive melanoma (lentigo maligna melanoma) in many people, and so must be managed carefully. These lesions occur predominantly on the face.
  • Biopsy is indicated for changing pigmented lesions on the face.
  • Where lentigo maligna is histologically confirmed, complete excision is the preferred management.
  • For some patients, treatment by observation for change, with measurement, is an acceptable alternative to immediate excision
  • A Wood light is helpful to determine the extent of the lentigo maligna.
  • Cryotherapy and shave biopsies should be left to the discretion of a specialist.
 

Back to contents>>

  1. HISTOPATHOLOGICAL REPORT
An accurate histopathology report is an essential prerequisite for optimal therapy for melanoma.
  • Request forms for pathology should include adequate patient identification, and clinical details of all lesions removed.
  • Where more than one lesion is excised, separate specimen bottles are essential.
  • The pathologist's report should include all important features of the lesions. (Histopathologic Type, Tumor thickness and ulceration)
  • Tumour thickness, ulceration and clearance margins are essential. A standardised format of histological reporting on melonoma is advocated
  • Where clinical and pathological diagnoses do not concur, a second opinion should be sought from a pathologist with expertise in the diagnosis of pigmented tumours.
 

Back to contents>>

  1. CLASSIFICATION OF MELANOMA
Use of the AJCC/UICC classification system (2002) is recommended.15

The primary tumour categories in the TNM classification are based on 2 microstaging systems: 1. Clark system – describes the level of microinvasion through the layers of the dermis. This is now mainly of historic value and relevant only for very thin melanomas. It gets replaced by the Breslow thickness – which is considered the most important diagnositc factor for primary melanoma. The thickness is measured in millimetres from the granular cell layer to the base of the lesion and is divided into 4 groups:
  • <0.75 mm;
  • 0.75-1.50 mm;
  • > 1.50- 4 mm;
  • > 4 mm.
TX Primary tumor cannot be assessed (e.g., shave biopsy or regressed melanoma)
T0 No evidenceof primary tumor
Tis Melanoma in situ
T1 Melanoma < 1.0 mm in thickness with or without ulceration
T1a Melanoma < 1.0 mm in thickness and level II or III, no ulceration
T1b Melanoma < 1.0 mm in thickness and level IV or V with ulceration
T2 Melanoma 1.01 – 2 mm in thickness with or without ulceration
T2a Melanoma 1.01 – 2.0 mm in thicknss, no ulceration
T2b Melanoma 1.01 – 2.0 mm in thicknss, with ulceration
T3 Melanoma 2.01 – 4 mm in thickness, with or without ulceration
T3a Melanoma 2.01 – 4.0 mm in thickness, no ulceration
T3b Melanoma 2.01 – 4.0 mm in thickness, with ulceration
T4 Melanoma greater than 4.0 mm in thickness with or without ulceration
T4a Melanoma > 4.0 mm in thickness, no ulceration
T4b Melanoma > 4.0 mm in thickness, with ulceration
N.B Note that Clarke level is only important for thin Melanomas (T1)
   
Regional Lymph Nodes (N)16
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastsis
N1 Metastasis in one lymph node
N1a Clinically occult (microscopic) metastasis
N1b Clinically apparent (macrospopic) metastasis
N2 Metastasis in two to three regional nodes or intra-lymphatic regional metastasis without nodal metastases
N2a Clinically occult (microscopic) metastasis
N2b Clinically apparent (macroscopic) metastasis
N2c Satellite or in-transit metastasis without nodal metastasis
N3 Metastasis in four or more regional nodes, or mated metastatic nodes, or in-transit metastsis or satellite(s) with metastasis in regional node(s)
   
Distant Metastasis (M)16
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
M1a Metastasis to skin, subcutaneous tissues or distant lymph nodes
M1b Metastasis to lung
M1c Metastasis to all other visceral sites or distant metastasis an any site associated with an elevated secrum lactic dehydrogenase (LDH)
   

 

Back to contents>>

  1. TREATMENT OF PRIMARY MELANOMA
  • The AJCC/UICC system (2002) is recommended as the basis for melanoma therapy.16

  • Complete excision with margins determined by tumour thickness measurement should be the basis for management of primary melanomas

  • A minimum margin of 1 cm and a maximum margin of 3cm should be used for invasive melanoma, with a choice of excision margin determined by tumour thickness. A depth of excision equal to the margin is advised but is not necessary to excise further than the deep fascia.

  • Other pathological features should be used to make an assessment of prognosis and modify management decisions In very thin lesions, thickness alone does not accurately predict the prognosis.
The following is recommended 46-49
1. (pTis) Melanoma in situ -margin 5mm
2. (pT1, pT2) Melanoma 0-1.5 -margin 1 cm
3. (pT3) Melanoma 1.5-4.0 -minumum margin 1cm
and maximum margin 2cm
4. (pT4) Melanoma > 4.0mm -minimum margin 2cm
and maximum margin 3cm
 
It should be notes that there is no evidence that a margin greater than 1cm offers additional benefit to the patient in terms of survival but it may decrease local recurrence.47-50

  • Primary lesions in special sites should be referred to a specialist centre
 

Back to contents>>

  1. SURVIVAL OUTCOMES OF PRIMARY MELANOMA MANAGEMENT
  • Survival after diagnosis of melanoma falls with increasing tumour thickness.51-52 To advise patients on the likely outcome of their primary melanoma management, the following estimates may be given for 5 year survival rates from the AJCC 2002:

Five-year survival rates of pathologically staged patients (adapted from Blach et al.)16

  IA IB IIA IIB IIC IIIA IIIB IIIC
Ta: Non- T1a T2a T3a T4a   N1a N1b N3
ulcerated 95% 89% 79% 67%   N2a N2b  
Melanoma           67% 54% 28%
                 

Tb:   T1b T2b T3b T4b   N1a N1b
Ulcerated   91% 77% 63% 45%   N2a N2b
Melanoma               N3
              52% 24%
                 

  • Other prognostic variables influence outcomes. Such factors as a thin melanoma which reaches Clark level 4, ulceration, the presence of lymphatic invasion, satellites and high mitotic rate may adversely affect the prognosis for the individual patients with melanoma.53,54


 

Back to contents>>

  1. TREATMENT OF LYMPH NODES

All patients with invasive melanoma are at risk for metastases to the lymph nodes. Metastases to lymph nodes are uncommon for melanomas <1.0mm in tumour thickness. For primary melanomas 1.0mm and greater in thickness, an increasing proportion of patients will develop regional lymph node involvement. At least 25% of melanomas between 1.5mm and 4.0mm thick will have microscopic lymph node involvement at the time of primary diagnosis. Sixty per cent of melanomas thicker than 4.0mm will have nodal involvement 55-57, but these involved nodes are usually not clinically apparent at the time of primary diagnosis.

  • Needle aspiration is preferable to excision biopsy of lymph nodes suspicious of metastatic melanoma.51 This should only be performed by doctors who are thoroughly familiar with the technique. If the local radiologist has expertise in UIS of nodes then it may be appropriate to do U/S and proceed directly to a block dissection if nodes are suspicious.

  • Excision biopsy of suspicious nodes should be followed by node dissection immediately if nodal metastases are detected.51

  • Elective lymph node dissection is generally not recommended.58-62,63-66

  • Therapeutic node dissection should be undertaken only by surgeons traines in these procedures. 67,68,69-74

  • The recent surgical technique of lymphatic mapping and selective node biopsy provides an alternative approach to the treatment of melanoma >1mm thick. 69-71 Sentinel node biopsy means identification of the first lymph nodes (the sentinel nodes) to take up radioactive tracer injected around a primary site. These nodes are then marked on the skin and identified at surgery by injection of patent blue dye. The blue stained nodes are selectively biopsied and examined by histology and immune histochemistry. Should they be positive the lymph nodes get dissected. This ensures that patients with nodal involvement are subjected to full regional lymph node dissection.
    Sentinel node biopsy should only be performed by surgeons trained in this procedure.


    Adequate node dissection is associated with a reasonably good prognosis, with a 10-year survival of up to 50% where only one node is involved. Even when two or three nodes are involved, 10-year survival rates of up to 30% can be achieved. 51 However, extranodal spread is associated with a high fatality rate, and radiotherapy could be considered if this is detected, if the nodes are extensively involved or if tumour spillage occurs during the surgery.

  • CT scans could be used to assess the iliac nodes where inguinal lymph node dissection is contemplated.
 

Back to contents>>

  1. OCCULT PRIMARY MELANOMA
  • Melanoma in lymph nodes or systemic metastases should be treated in accordance with guidelines regardless of the inability to detect the primary lesion.75-78


 

Back to contents>>

  1. LOCOREGIONAL RECURRENT MELANOMA
  • Excision of a single local or regional metastasis is the treatment of choice.

  • Limb perfusion in a specialised centre should be considered if satellite lesions are present. 79-82


 

Back to contents>>

  1. ADJUVANT THERAPY
  • Patients with melanomas >4mm thick or with lymph node metastases should be referred to a specialised centre for consideration for adjuvant therapy.
 

Back to contents>>

  1. DISSEMINATED MELANOMA
  • Patients with systemic metastases should be referred to a specialised centre for consideration for systemic therapies.

  • All clinicians dealing with patients with systemic melanoma should be appropriately skilled in psychological management and palliative care.83-85

  • Surgical resection should be considered for isolated melanoma metastases in lung, brain and peritoneal cavity.86 Multiple subcutaneous metastases may be well controlled with surgery in some cases if the patient is followed up carefully.

 

Back to contents>>

  1. RADIOTHERAPY FOR MELANOMA
  • Post-operative radiotherapy could be considered for cutaneous melanomas likely to recur e.g. where wide resection of the primary tumour is not feasible, as sometimes happens on the face. 87

  • or regionally (multiple node involvement or extra-capsular spread) and following resection of mucosal melanomas. Primary radiotherapy should be considered for unresectable lentigo maligna melanomas or large unresectable primary lesions in the elderly and frail. 87

  • Radiotherapy may be recommended for treatment of extensive cutaneous metastases where surgery is not feasible and for palliative management of cerebral and bone metastases and for other metastases where temporary local control is needed eg. large nodal or soft tissue masses.88-91
 

Back to contents>>

  1. PALLIATIVE CARE
  • Educating patients and carers as to the behaviour of metastatic melanoma with its unique features (i.e. subcutaneous spread and acute episodes of pain due to bleeding) and the appropriate intervention will assist them in coping with the disease.

  • Clinicians should be aware of the palliative care services available within the patient's community, so that referral can be made if the patient so wishes
 

Back to contents>>

  1. FOLLOW UP
  • A follow-up regimen based on tumour thickness should be arranged for all patients with melanoma.92,93

  • The follow-up examination should include palpation for local recurrence, in-transit and lymph node metastases and signs of systemic relapse .A general examination of the skin for new primary melanomas and other skin cancers should be performed
 

Back to contents>>

  1. APPROPRIATE INVESTIGATIONS
  • Extensive investigation for systemic metastases in patients with primary melanoma is not recommended. 94-96 Baseline investigations such as a FBC, CXR and liver functions, including LDH, may be undertaken. Patients with deep lesions should have a CT chest and upper abdomen. The latter may serve as a baseline for future comparison.

  • Generally investigation such as MRI and PET (Position Emission Tomography) should be utilised only where specific symptoms suggest the presence of metastases.
 

Back to contents>>

  1. SPECIFIC SITES AND TYPES OF MELANOMA
  • Mucosal melanoma
Mucosal melanoma is rare, comprising <1% of all melanoma. It occurs in the mouth, nose, oesophagus, gall bladder, urethra, anus, vulva and vagina, and is usually asymptomatic. 97,98 For this reason mucosal melanoma is generally detected late and thus has a very poor prognosis. 99

Patients with mucosal melanoma should be referred to a suitable speciality clinic or clinician.
  • Acral Lentiginous Melanoma (ALM)

Acral lentiginous melanoma is defined as melanoma of the acral skin, i.e. the thickened skin of the soles and palms. The main interest of the ALM classification is that it is the predominant melanoma of non-white individuals. Its prognosis may be marginally worse than other melanomas but this is yet to be conclusively proven. 100-102

ALM on the sole of the foot should be referred for specialist excision and appropriate reconstructive procedures and therapies.
  • Subungual melanoma
Subungual melanoma should be considered as a possible cause of any pigmentary changes under the nail. 103 In cases of doubt, removal of the nail and biopsy is recommended. 104-106 Subungual melanoma should be treated with excision margins which accord to the lesion thickness. This usually involves amputation of the terminal phalanx. 104 Because most subungual melanomas are advanced at the time of presentation, elective node dissection may be apprpriate for these patients. 107,108 Naevi on the soles of the feet or on the genitals of patients should not be removed routinely, because the incidence of malignant transformation of the theses lesions is not higher than that of other lesions.
  • Desmoplastic Melanoma

Desmoplastic and neurotropic melanomas are associated with a high risk of local recurrence related to their poorly defined clinical borders, frequent amelanosis and infiltration along nerve sheaths, predisposing to incomplete excision and persistence of the primary tumour. 109,110

Wider excision than is normal for other histological types of melanoma is recommended for Desmoplastic Melanoma. Post operative radiotherapy, in consultation with a specialist should be considered after surgical excision of a recurrent Desmoplastic or Neurotropic Melanoma.
  • Multiple Primary Melanoma
Multiple new primary melanomas may occur in at least 5% of patients with melanoma. 111-113 They are more common in patients with multiple atypical naevi especially in a familial melanoma setting but can occur in any patients who has had a melanoma.114-115

Multiple Primary Melanoma should be treated according to the tumour thickness of each lesion. 116
  • Melanoma in Childhood
Melanoma is rare in children below the age of 12, but clinical features are identical to those in the adult. 116

Melanoma in children should be treated as appropriate for the same tumour thickness as melanoma in the adult. 117-118
  • Melanoma During Pregnancy
Melanoma in a pregnant woman should be treated according to the tumour thickness. 119-121 It has not been conclusively demonstrated that pregnancy alters the prognosis in a patient who has a melanoma diagnosed either before or during pregnancy. 120 Pregnant women with thicker melanomas and nodal metastases should be treated in consultation with specialised centres and psychological support may need to be obtained. Because of the possibility of metastatic recurrence, pregnancy is not advisable for two years after removal of high risk primary melanoma or melanoma in nodes. 122 Termination of pregnancy should be considered in women with high risk primary or recurrent melanoma only after detailed discussion with the patient and her partner.
  • Hormone Replacement Therapy and Oral Contraceptives
Hormone replacement therapy and oral contraceptives are not contraindicated for women who have or have had melanoma. 123,124

Disclaimer: This document is a general guide to appropriate practice, to be followed only subject to clinicians judgement in each individual case. It is compiled by Members of the Melanoma Advisory Board, a multidisciplinary forum consisting of Dermatologists, Oncologists, Plastic Surgeons and Pathologists. The guidelines are designed to provide information to assist decision making and are based on the best information available at the date of compilation (November 2003).
 

Back to contents>>